{"id":1625,"date":"2020-03-12T15:15:35","date_gmt":"2020-03-12T14:15:35","guid":{"rendered":"http:\/\/oncngs.eu\/?page_id=1625"},"modified":"2023-02-07T12:49:56","modified_gmt":"2023-02-07T11:49:56","slug":"phase1","status":"publish","type":"page","link":"https:\/\/oncngs.eu\/index.php\/phase1\/","title":{"rendered":"Phase I : Solution design"},"content":{"rendered":"<p>[vc_row][vc_column][vc_column_text]<\/p>\n<p style=\"font-family: Rubik; color: black;\">During Phase 1 the contractors will perform research to:<\/p>\n<p style=\"font-family: Rubik; color: black;\">1. elaborate the solution design and determine the approach to be taken to develop the new solutions and:<\/p>\n<p style=\"font-family: Rubik; color: black;\">2. demonstrate the technical, financial and commercial feasibility of the proposed concepts and approach to meet the procurement need.<\/p>\n<p>&nbsp;<\/p>\n<p style=\"font-family: Rubik; color: black;\"><strong>Phase 1 Awards:<\/strong><\/p>\n<p style=\"font-family: Rubik; color: black;\">Budget of awarded contracts: 642.399,78 EUR<\/p>\n<p style=\"font-family: Rubik; color: black;\">Tender received: 7<\/p>\n<p style=\"font-family: Rubik; color: black;\">Number of contracts awarded: 4<\/p>\n<p>&nbsp;<\/p>\n<p style=\"font-family: Rubik; color: black;\"><strong>Selected tenders:<\/strong><\/p>\n<p style=\"font-family: Rubik; color: black;\"><strong>&#8211; HUFIAT CANCER LIQUIDATION<\/strong><\/p>\n<p style=\"font-family: Rubik; color: black;\">\u00a0\u00a0 &#8211; Lead: Euformatics Oy<\/p>\n<p style=\"font-family: Rubik; color: black;\">\u00a0\u00a0 &#8211; Consortium members: Euformatics Oy, Oncompas Medicine, ViennaLab Diagnostics<\/p>\n<p style=\"font-family: Rubik; color: black;\"><strong>&#8211; KU LEUVEN <\/strong><\/p>\n<p style=\"font-family: Rubik; color: black;\"><strong>&#8211; AGILENT <\/strong><strong>TECHNOLOGIES BELGIUM<br \/>\n<\/strong><\/p>\n<p style=\"font-family: Rubik; color: black;\"><strong>&#8211; ONCODNA<\/strong><\/p>\n<p>&nbsp;<\/p>\n<p style=\"font-family: Rubik; color: black;\"><strong>Duration : 4 months (31st January to 30th May 2023)<br \/>\n<\/strong><\/p>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_separator color=\u00a0\u00bbgreen\u00a0\u00bb][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]<\/p>\n<h1>Other phases<\/h1>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_btn title=\u00a0\u00bbPhase 0 : Curiosity Driven Research\u00a0\u00bb link=\u00a0\u00bburl:http%3A%2F%2Foncngs.eu%2Findex.php%2Fphase-0-curiosity-driven-research%2F|title:Phase%200%20%3A%20Curiosity%20Driven%20Research||\u00a0\u00bb][vc_empty_space height=\u00a0\u00bb2px\u00a0\u00bb][vc_btn title=\u00a0\u00bbPre-commercial Procedure\u00a0\u00bb link=\u00a0\u00bburl:http%3A%2F%2Foncngs.eu%2Findex.php%2Ftender%2F|title:Pre-commercial%20Procedure||\u00a0\u00bb][vc_empty_space height=\u00a0\u00bb2px\u00a0\u00bb][vc_btn title=\u00a0\u00bbPhase II: Prototype development\u00a0\u00bb link=\u00a0\u00bburl:http%3A%2F%2Foncngs.eu%2Findex.php%2Fphase2%2F|title:Phase%20II%3A%20Prototyping%20and%20Analytical%20testing||\u00a0\u00bb][vc_empty_space height=\u00a0\u00bb2px\u00a0\u00bb][vc_btn title=\u00a0\u00bbPhase III : Clinical validation of a limited set of pre-commercial devices\u00a0\u00bb link=\u00a0\u00bburl:http%3A%2F%2Foncngs.eu%2Findex.php%2Fphase3%2F|title:Phase%20III%20%3A%20Clinical%20validation%20of%20a%20limited%20set%20of%20pre-commercial%20devices%20%2F%20Clinical%20testing||\u00a0\u00bb][\/vc_column][\/vc_row][vc_row][vc_column][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"[vc_row][vc_column][vc_column_text] During Phase 1 the contractors will perform research to: 1. elaborate the solution design and determine the approach to be taken to develop the new solutions and: 2. demonstrate the technical, financial and commercial feasibility of the proposed concepts and approach to meet the procurement need. &nbsp; Phase 1 Awards: Budget of awarded contracts:[&#8230;]","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"_links":{"self":[{"href":"https:\/\/oncngs.eu\/index.php\/wp-json\/wp\/v2\/pages\/1625"}],"collection":[{"href":"https:\/\/oncngs.eu\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/oncngs.eu\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/oncngs.eu\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/oncngs.eu\/index.php\/wp-json\/wp\/v2\/comments?post=1625"}],"version-history":[{"count":16,"href":"https:\/\/oncngs.eu\/index.php\/wp-json\/wp\/v2\/pages\/1625\/revisions"}],"predecessor-version":[{"id":2460,"href":"https:\/\/oncngs.eu\/index.php\/wp-json\/wp\/v2\/pages\/1625\/revisions\/2460"}],"wp:attachment":[{"href":"https:\/\/oncngs.eu\/index.php\/wp-json\/wp\/v2\/media?parent=1625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}